Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab.
Go
Aileen
A
Rush University Medical Center Chicago, Ill, USA. aileen_go@rush.edu
Venugopal
Parameswaran
P
Loew
Jerome
J
Djordjevic
Dragan
D
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D002490:Central Nervous System / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed / Q000379:methods; D016896:Treatment Outcome; D019043:Vascular Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab